Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma

This study tests ADI-PEG 20 — a drug that depletes arginine, an amino acid that some liver cancers depend on to survive — in patients with unresectable liver cancer (hepatocellular carcinoma, or HCC) who have elevated arginine levels in their blood. The idea is that starving the tumor of arginine may slow its growth. **You may be eligible if...** - You have a confirmed diagnosis of HCC (by imaging, biopsy, or cytology) - Your cancer cannot be surgically removed - Your blood arginine level is 78 μM or higher (measured at a pre-screening visit) - You have at least one measurable tumor - You have received prior treatment with at least one systemic therapy (for Child-Pugh A patients); Child-Pugh B7 patients with no prior systemic treatment may be eligible if approved therapies are not accessible **You may NOT be eligible if...** - Your arginine levels are below the required threshold - You have severe liver dysfunction (Child-Pugh C) - You have had recent major surgery or active serious infection - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.